

---

**Amendments to the Claims**

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

**Listing of Claims**

Claims 1-57 (Cancelled Herein)

58. (New) An immunostimulatory composition suitable for administration to a human subject in need of immunotherapy comprising:

(i) at least one Toll-Like Receptor (TLR) agonist;

(ii) at least one CD40 agonist that directly binds CD40 and/or at least one 4-1BB agonist that directly binds 4-1BB; and a pharmaceutically acceptable carrier,

wherein (i) and (ii) are comprised in mounts such that, in combination with the other, are effective to produce a synergistic increase in a human subject in an immune response to an antigen upon administration to a human subject in need of immunotherapy.

59. (New) The immunostimulatory composition of claim 58 wherein the (i) at least one TLR agonist is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, and TLR9 agonists.

60. (New) The immunostimulatory composition of claim 58 wherein the at least one CD40 agonist comprises an agonistic anti-CD40 antibody or agonistic anti-CD40 antibody fragment.

61. (New) The immunostimulatory composition of claim 58 wherein the (ii) at least one CD40 agonist comprises a CD40 ligand (CD40L) L polypeptide or CD40L polypeptide fragment.

62. (New) The immunostimulatory composition of claim 58 wherein the (ii) at least one 4-1BB agonist comprises an anti-4-1BB antibody or anti-4-1BB antibody fragment.

63. (New) The immunostimulatory composition of claim 58 wherein the at least one 4-1BB agonist comprises a 4-1BB ligand polypeptide or 4-1BB ligand polypeptide fragment.

64. (New) The immunostimulatory composition of claim 58 wherein the at least one TLR agonist comprises an immune response modifier (IRM) compound or an agonist of TLR2.

65. (New) The immunostimulatory composition of claim 58 wherein the at least one TLR agonist comprises an ORM compound, MALP-2, Pam3cys, LPS, polyIC., CpG, or any combination of any of the foregoing.

66. (New) The immunostimulatory composition of claim 58 wherein the at least one TLR agonist comprises an imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazonaphthyridine amine, or a thiazolonaphthyridine amine.

67. (New) The immunostimulatory composition of claim 58 wherein the at least one CD40 agonist comprises an anti-CD40 agonistic antibody.

68. (New) The immunostimulatory composition of claim 58 which is suitable for administration to a human subject in need of immunotherapy by a route selected from the group consisting of oral, nasal, topical, and injection.

69. (New) The immunostimulatory composition of claim 68 which is suitable for injection to a human subject in need of immunotherapy.

70. (New) The immunostimulatory composition of claim 69 wherein injection is selected from the group consisting of subcutaneous, intravenous, intraperitoneal, intramuscular and intravenous. .

71. (New) The immunostimulatory composition of claim 58 wherein the at least one TLR agonist is a TLR9 agonist.

72. (New) The immunostimulatory composition of claim 71 wherein the TLR agonist comprises a CpG compound.

73. (New) A vaccine composition suitable for administration to a human subject in need thereof comprising:

(i) at least one TLR agonist;

(ii) at least one CD40 agonist that directly binds CD40 and/or at least one 4-1BB agonist that directly binds 4-1BB;

(iii) at least one antigen; and at least one pharmaceutically acceptable carrier;

wherein (i) and (ii) are each comprised in an amount that, in combination with the other, are effective for inducing a synergistic immune response to the (iii) antigen in a human subject upon administration of the vaccine.

74. (New) The vaccine composition of claim 73 wherein the (i) at least one TLR agonist is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, and TLR9 agonists.

75. (New) The vaccine composition of claim 73 wherein the at least one CD40 agonist comprises an agonistic anti-CD40 antibody or an agonistic anti-CD40 antibody fragment.

76. (New) The vaccine composition of claim 73 wherein the (ii) at least one CD40 agonist comprises a CD40 ligand (CD40L) polypeptide or CD40L polypeptide fragment.

77. (New) The immunostimulatory composition of claim 73 wherein the (ii) at least one 4-1BB agonist comprises an agonistic anti-4-1BB antibody or agonistic anti-4-1BB antibody fragment.

78. (New) The immunostimulatory composition of claim 73 wherein the at least one 4-1BB agonist comprises a 4-1BB ligand polypeptide or a 4-1BB ligand polypeptide fragment.

79. (New) The vaccine composition of claim 73 wherein the at least one TLR agonist comprises an immune response modifier (IRM) compound or an agonist of TLR2.

80. (New) The vaccine composition of claim 73 wherein the TLR agonist comprises an IRM compound, MALP-2, Pam3cys, LPS, polyIC<sub>2</sub>, CpG<sub>2</sub> or any combination of any of the foregoing.

81. (New) The vaccine composition of claim 73 wherein the TLR agonist comprises an imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an

**Amendment and Response**

Serial No.: 10/748,010

Confirmation No.: 7654

Filed: 30 December 2003

For: IMMUNOSTIMULATORY COMBINATIONS

---

Page 5 of 22

imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolophthyridine amine, or a thiazolophthyridine amine.

82. (New) The vaccine composition of claim 73 wherein the at least one CD40 agonist comprises an anti-CD40 agonistic antibody.

83. (New) The vaccine composition of claim 73 which is suitable for administration to a human subject in need of immunotherapy by a route selected from the group consisting of oral, nasal, topical, and injection.

84. (New) The vaccine composition of claim 83 which is suitable for injection to a human subject in need of immunotherapy.

85. (New) The vaccine composition of claim 84 wherein injection is selected from the group consisting of subcutaneous, intravenous, intraperitoneal, intramuscular and intravenous. .

86. (New) The vaccine composition of claim 73 wherein the at least one TLR agonist comprises a TLR9 agonist.

87. (New) The vaccine composition of claim 86 wherein the at least one TLR9 agonist comprises a CpG compound.

88. (New) The vaccine composition of claim 73 wherein the at least one TLR agonist comprises an agonist of TLR7, TLR8 or TLR9.

89.. (New) The vaccine composition of claim 73 wherein the at least one TLR agonist comprises an agonist of TLR8.

90. (New) The vaccine composition of claim 73 wherein the at least one TLR agonist comprises an agonist of TLR7.

91. (New) A method of human immunotherapy which comprises administering to a human subject in need thereof an immunostimulatory composition according to claim 58 under conditions that elicit a synergistic effect on an immune response to an antigen.

**Amendment and Response**

Serial No.: 10/748,010

Confirmation No.: 7654

Filed: 30 December 2003

For: IMMUNOSTIMULATORY COMBINATIONS

---

Page 6 of 22

92. (New) The method of claim 91 wherein the immunostimulatory composition is administered via injection.
93. (New) The method of claim 92 wherein injection is selected from the group consisting of intraperitoneal, intramuscular, intravenous, and subcutaneous.
94. (New) The method of claim 91 wherein the immunostimulatory composition comprises a CD40 agonistic antibody or agonistic anti-CD40 antibody fragment.
95. (New) The method of claim 91 wherein the immunostimulatory composition comprises an agonistic CD40L polypeptide or an agonistic CD40L polypeptide fragment.
96. (New) The method of claim 91 wherein the at least one TLR agonist comprised in the administered immunostimulatory composition is selected from the group consisting of a TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, and TLR9 agonist.
97. The method of claim 96 wherein the at least one TLR agonist comprises a TLR7, TLR8, or TLR9 agonist.
98. (New) The method of claim 91 wherein the administered immunostimulatory composition comprises a 4-1B agonist which comprises an agonistic anti-4-1BB antibody or agonistic anti-4-1BB antibody fragment or a 4-1BB ligand polypeptide.
99. (New) A method of immunotherapy which comprises administering to a human subject in need thereof a vaccine composition according to claim 73 under conditions that elicit a synergistic increase in an immune response to an antigen.
100. (New) The method of claim 99 wherein the vaccine composition is administered via an injection route.
101. (New) The method of claim 100 wherein injection route is selected from the group consisting of intraperitoneal, intramuscular, intravenous, and subcutaneous.
102. (New) The method of claim 99 wherein the vaccine composition comprises a CD40 agonistic antibody or agonistic anti-CD40 antibody fragment.
103. (New) The method of claim 99 wherein the vaccine composition comprises a CD40L polypeptide or a CD40L polypeptide fragment.

**Amendment and Response**

Page 7 of 22

Serial No.: 10/748,010

Confirmation No.: 7654

Filed: 30 December 2003

For: IMMUNOSTIMULATORY COMBINATIONS

---

104. (New) The method of claim 99 wherein the vaccine comprises a TLR agonist selected from the group consisting of a TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, and TLR9 agonist.

105. (New) The method of claim 104 wherein the TLR agonist is a TLR7, TLR8, or TLR9 agonist.

106. (New) The method of claim 99 wherein the vaccine comprises an anti-4-1BB agonistic antibody, or an agonistic anti-4-1BB antibody fragment.

107. (New) The method of claim 99 wherein the administered vaccine comprises a tumor antigen, a viral antigen, a bacterial antigen, or a parasitic antigen.